Frontal Fibrosing Alopecia

MarketVue®: Frontal Fibrosing Alopecia

The MarketVue®: Frontal Fibrosing Alopecia market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.

Topics covered in this report:
• Disease overview: Review the disease pathophysiology and potential druggable targets
• Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
• Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
• Unmet needs: Identify opportunities to address treatment or disease management gaps
• Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
• Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing

Methodology:
Research for the MarketVue®: Frontal Fibrosing Alopecia report is supported by 6 qualitative interviews with key opinion leaders, a quantitative survey with 25 U.S. physicians and secondary research.

Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)

Key companies mentioned:
• LEO Pharma
• Pfizer

Key drugs mentioned:
• Finasteride
• Dutasteride
• Tacrolimus
• Pimecrolimus
• Hydroxychloroquine
• Tetracycline
• Minoxidil
• Methotrexate
• Mycophenolate mofetil
• Pioglitazone
• Naltrexone
• Apremilast
• Baricitinib (Olumiant)
• Delgoticinib
• Ritlecitinib

Key takeaways from the report:
Since the June 2022 approval of Eli Lilly’s Olumiant (baricitinib), the AA market landscape has been dynamic with two more oral JAK inhibitors (e.g., Pfizer’s ritlecitinib and SUN/Concert Pharmaceutical’s deuruxolitinib) likely to be approved in the next year. In contrast, there is no FDA-approved treatment for FFA, a rare hair loss condition with a high clinical and psychosocial burden marked by frontal hairline recession and inflammation causing itching, pain, and burning.
Currently, FFA patients are managed primarily with off-label:
• Corticosteroids
• JAK inhibitors
• Non-steroidal immunosuppressants
However, JAK inhibitor use is not widespread (<10% of patients) mostly due to insurance restrictions. Physicians are eager for treatment options indicated specifically for FFA able to achieve complete response defined as stopping hair loss and inflammatory progression of the disease. Currently, about half of all patients achieve this goal, as one interviewed dermatologist states: “The condition will eventually burn out spontaneously, so we are preventing follicular loss in patients who are going to otherwise lose a lot of their hair permanently.”
Despite the high unmet need for effective treatments, the FFA pipeline is sparse, with few options under investigation including:
• LEO Pharma’s topical pan-JAK delgocitinib
• Pfizer’s TEC/JAK3 ritlecitinib through an investigator-initiated study
With no indication that Pfizer plans to apply for a label extension, there is opportunity for other pharmaceutical companies to develop treatments for FFA and own a significant share of the market.
Pooja Patel, Analyst at REACH: “With very few therapies in development for FFA, dermatologists will continue to rely upon off-label treatments. Although the first approved therapy will likely be a JAK inhibitor, dermatologists agree they would like to see more research into the pathophysiology of the disease to identify more druggable targets such as the IL-17/23 pathway, interferon gamma, and retinoic acid receptors.”

Please note: the online download version of this report is for a global site license.